StocksMediumUpdated•Originally published 9 March 2026•Updated 9 March 2026•
1 min read
MBX Biosciences Issues Technical Correction Following Successful FDA Meeting for Canvuparatide
Key Facts
1MBX Biosciences announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA.
2The meeting discussed the Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism.
3The company plans to move forward with the Phase 3 development plan based on the meeting outcomes.
MBX Biosciences has successfully concluded its End-of-Phase 2 meeting with the U.S. FDA regarding the Phase 3 trial design for canvuparatide. The candidate is being developed as a once-weekly treatment for chronic hypoparathyroidism. Following the milestone announcement, the company issued a technical correction to clarify the dosage units for the drug. MBX specified that the correct unit of measurement for canvuparatide is micrograms, correcting a previous reference to milligrams. This adjustment ensures the accuracy of clinical documentation as the company prepares to launch its late-stage trials. MBX remains focused on advancing its peptide-based therapeutic platform to address significant unmet needs in rare endocrine disorders.